These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 38516474)

  • 61. Fluoroquinolones: action and resistance.
    Drlica K; Malik M
    Curr Top Med Chem; 2003; 3(3):249-82. PubMed ID: 12570763
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Involvement of topoisomerase mutations and qnr and aac(6')Ib-cr genes in conferring quinolone resistance to clinical isolates of Vibrio and Shigella spp. from Kolkata, India (1998-2009).
    Vinothkumar K; Bhalara SR; Shah A; Ramamurthy T; Niyogi SK; Kumar GN; Bhardwaj AK
    J Glob Antimicrob Resist; 2018 Jun; 13():85-90. PubMed ID: 29111483
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A mutation in Escherichia coli DNA gyrase conferring quinolone resistance results in sensitivity to drugs targeting eukaryotic topoisomerase II.
    Gruger T; Nitiss JL; Maxwell A; Zechiedrich EL; Heisig P; Seeber S; Pommier Y; Strumberg D
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4495-504. PubMed ID: 15561817
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Engineering the specificity of antibacterial fluoroquinolones: benzenesulfonamide modifications at C-7 of ciprofloxacin change its primary target in Streptococcus pneumoniae from topoisomerase IV to gyrase.
    Alovero FL; Pan XS; Morris JE; Manzo RH; Fisher LM
    Antimicrob Agents Chemother; 2000 Feb; 44(2):320-5. PubMed ID: 10639357
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Fluoroquinolone antibiotics. Microbiology, pharmacokinetics and clinical use.
    Paton JH; Reeves DS
    Drugs; 1988 Aug; 36(2):193-228. PubMed ID: 3053126
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Bypassing fluoroquinolone resistance with quinazolinediones: studies of drug-gyrase-DNA complexes having implications for drug design.
    Drlica K; Mustaev A; Towle TR; Luan G; Kerns RJ; Berger JM
    ACS Chem Biol; 2014 Dec; 9(12):2895-904. PubMed ID: 25310082
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Mutations in topoisomerase IV and DNA gyrase of Staphylococcus aureus: novel pleiotropic effects on quinolone and coumarin activity.
    Fournier B; Hooper DC
    Antimicrob Agents Chemother; 1998 Jan; 42(1):121-8. PubMed ID: 9449271
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Mechanisms for the development of quinolone resistance].
    Kojima M
    Nihon Rinsho; 1997 May; 55(5):1252-60. PubMed ID: 9155183
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Antimicrobial activity of a new fluoroquinolone, DU-6859a, against quinolone-resistant clinical isolates of Neisseria gonorrhoeae with genetic alterations in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV.
    Deguchi T; Yasuda M; Nakano M; Kanematsu E; Ozeki S; Ishihara S; Saito I; Kawada Y
    J Antimicrob Chemother; 1997 Feb; 39(2):247-9. PubMed ID: 9069547
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Quinolone resistance in bacteria: emphasis on plasmid-mediated mechanisms.
    Li XZ
    Int J Antimicrob Agents; 2005 Jun; 25(6):453-63. PubMed ID: 15890498
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Do we need an intravenous fluoroquinolone?
    Maddix DS; Warner L
    West J Med; 1992 Jul; 157(1):55-9. PubMed ID: 1413744
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Quinolones inhibit DNA religation mediated by Staphylococcus aureus topoisomerase IV. Changes in drug mechanism across evolutionary boundaries.
    Anderson VE; Zaniewski RP; Kaczmarek FS; Gootz TD; Osheroff N
    J Biol Chem; 1999 Dec; 274(50):35927-32. PubMed ID: 10585479
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Molecular determinants of the bacterial resistance to fluoroquinolones: a computational study.
    Lupala CS; Gomez-Gutierrez P; Perez JJ
    Curr Comput Aided Drug Des; 2013 Jun; 9(2):281-8. PubMed ID: 23106777
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Examining the Impact of Antimicrobial Fluoroquinolones on Human DNA Topoisomerase IIα and IIβ.
    Fief CA; Hoang KG; Phipps SD; Wallace JL; Deweese JE
    ACS Omega; 2019 Feb; 4(2):4049-4055. PubMed ID: 31459613
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Safety profile of the fluoroquinolones: focus on levofloxacin.
    Liu HH
    Drug Saf; 2010 May; 33(5):353-69. PubMed ID: 20397737
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Topoisomerase IV-quinolone interactions are mediated through a water-metal ion bridge: mechanistic basis of quinolone resistance.
    Aldred KJ; McPherson SA; Turnbough CL; Kerns RJ; Osheroff N
    Nucleic Acids Res; 2013 Apr; 41(8):4628-39. PubMed ID: 23460203
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Advances in DNA gyrase inhibitors.
    Kim OK; Ohemeng K; Barrett JF
    Expert Opin Investig Drugs; 2001 Feb; 10(2):199-212. PubMed ID: 11178337
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Molecular mechanism of fluoroquinolones resistance in Mycoplasma hominis clinical isolates.
    Meng DY; Sun CJ; Yu JB; Ma J; Xue WC
    Braz J Microbiol; 2014; 45(1):239-42. PubMed ID: 24948939
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Bacterial topoisomerases, anti-topoisomerases, and anti-topoisomerase resistance.
    Hooper DC
    Clin Infect Dis; 1998 Aug; 27 Suppl 1():S54-63. PubMed ID: 9710672
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Pharmacological properties and expected clinical role of an injectable new quinolone antibiotic, pazufloxacin mesilate].
    Minami S; Hattori R; Matsuda A
    Nihon Yakurigaku Zasshi; 2003 Aug; 122(2):161-78. PubMed ID: 12890902
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.